Christopher Lindop - PAREXEL International Independent Director

<div class='logoBackup' style='background:#000000;color: white;font-size:3em;;'>PRX</div>
  Director
Mr. Christopher J. Lindop is Independent Director of Parexel International Corporationrationration. He is Chairman of the Audit and Finance Committee and a member of the Nominating and Corporationrationrate Governance Committee. From January 2007 to June 2016, Mr. Lindop served as Chief Financial Officer and Executive Vice President, Business Development of Haemonetics Corporationrationration, a global blood management company. From September 2003 to December 2006, he served as Chief Financial Officer of Inverness Medical Innovations, Inc., a global developer, manufacturer and marketer of medical diagnostic products. From June 2002 to September 2003, he served as an audit partner for Ernst Young LLP, an accounting firm. From 1991 to June 2002, Mr. Lindop served as an audit partner with the Boston office of Arthur Andersen LLP, an accounting firm.
Age: 57  Director Since 2006      
781 487-9900  http://www.parexel.com

Christopher Lindop Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 4.71 % which means that it generated profit of $4.71 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 15.1 % meaning that it created $15.1 on every $100 dollars invested by stockholders.
The company currently holds 671.5 M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives

DIRECTOR Since

Michael TrimbleOrigin Agritech Limited
2006
Michael BrownRegeneron Pharmaceuticals
1991
Huda ZoghbiRegeneron Pharmaceuticals
2016
Sanjay KhoslaZoetis
2013
Jeffrey SmithPerrigo Company Plc
2017
William YoungVertex Pharmaceuticals Incorpor
2014
Willie ReedZoetis
2014
Marc TessierLavigneRegeneron Pharmaceuticals
2011
Lloyd CarneyVertex Pharmaceuticals Incorpor
2019
William DoyleZoetis
2015
Paul BisaroZoetis
2015
William SteereZoetis
2013
James KangOrigin Agritech Limited
2010
Arthur RyanRegeneron Pharmaceuticals
2003
Terrence KearneyVertex Pharmaceuticals Incorpor
2011
Gary KunklePerrigo Company Plc
2009
Yingqi XiaOrigin Agritech Limited
2010
Linda RhodesZoetis
2017
Larry CordellOrigin Agritech Limited
2012
David GreenwayVertex Pharmaceuticals Incorpor
2017
Geoffrey ParkerPerrigo Company Plc
2016

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Return On Equity15.10
Return On Asset4.71
Profit Margin4.09
Operating Margin11.04
Current Valuation4.87 B
Shares Outstanding51.12 M
Shares Owned by Insiders2.00
Shares Owned by Institutions90.14
Number of Shares Shorted506.64 K
Price to Earning42.76